The latest announcement is out from Kymera Therapeutics (KYMR).
During the Company’s Annual Meeting on June 18, 2024, shareholders voted on key proposals including the election of three Class I directors for a three-year term, approval of executive compensation on an advisory basis, ratification of the company’s independent accounting firm, and an amendment to the stock option and incentive plan. Shareholders elected Pamela Esposito, Ph.D., Gorjan Hrustanovic, Ph.D., and Victor Sandor, M.D.C.M. as directors, endorsed the executive officers’ pay, confirmed Ernst & Young LLP as the accounting firm, and approved an amendment to the incentive plan regarding the evergreen provision. These decisions will shape the company’s governance and financial strategy moving forward.
Find detailed analytics on KYMR stock on TipRanks’ Stock Analysis page.
